Attenuated ZHX3 expression serves as a potential biomarker that predicts poor clinical outcomes in breast cancer patients
Authors You Y, Ma Y, Wang Q, Ye Z, Deng Y, Bai F
Received 17 August 2018
Accepted for publication 4 January 2019
Published 5 February 2019 Volume 2019:11 Pages 1199—1210
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 1
Editor who approved publication: Dr Rituraj Purohit
Yanjie You,1,* Yuhong Ma,1,* Qiang Wang,2,* Zhengcai Ye,3 Yanhong Deng,1 Feihu Bai1
1Department of Gastroenterology, Ningxia Hui Autonomous Region People’s Hospital, Yinchuan 750021, China; 2Department of Science and Education, Ningxia Hui Autonomous Region People’s Hospital, Yinchuan 750021, China; 3Endoscopy Center, Ningxia Hui Autonomous Region People’s Hospital, Yinchuan 750021, China
*These authors contributed equally to this work
Background: The ZHX family has recently been in the spotlight as an integrator and an indispensable node in carcinogenesis, whose expression is frequently dysregulated in multiple cancers. The current study provides a novel investigation of the expression profiles of ZHX factors in breast cancer.
Materials and methods: The mRNA levels of ZHXs and follow-up periods in breast cancer patients were mined through the Oncomine, Cancer Cell Line Encyclopedia, bc-GenExMiner, cBioPortal and Kaplan–Meier plotter databases. In addition, ZHX3 protein expression was examined in 98 primary tumor samples by immunohistochemistry to investigate its association with clinicopathological parameters and patient outcomes.
Results: We found that the transcriptional levels of ZHX1, ZHX2 and ZHX3 were not significantly altered in tumor tissues compared with those in nontumor tissues. ZHX2 and ZHX3 mRNA levels were observed to be positively correlated with estrogen receptor and progesterone receptor expression, while ZHX2 mRNA levels were negatively associated with HER2 expression. Survival analyses revealed that high mRNA levels of ZHX2 and ZHX3 correlated with better overall survival in patients with breast cancer. Immunohistochemical analysis revealed that patients with decreased ZHX3 protein levels had poorer outcomes. Multivariate analysis exhibited that ZHX3 expression may serve as an independent high-risk prognostic predictor.
Conclusion: Dysregulated expression of ZHXs may be involved in the progression of breast cancer and could serve as a novel biomarker and potential target for breast cancer.
Keywords: ZHX, breast cancer, data mining, immunohistochemistry, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]